Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Applying Pharmacogenomics in Drug Discovery and Development
91
15. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI,
Hageman JL, et al. A common haplotype in the complement regulatory gene factor
H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl
Acad Sci U S A 2005;102:7227–32.
16. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, Gregori G, Penha FM,
Moshfeghi AA, Zhang K, Sadda S, Feuer W, Rosenfeld PJ. Systemic complement inhibition
with eculizumab for geographic atrophy in age-related macular degeneration:
The COMPLETE study. Ophthalmology 2014;121:693–701.
17. Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration.
Ophthalmologica 2009;223:401–10.
18. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, Huff CD,
et al. Exome sequencing identifies the cause of a Mendelian disorder. Nat Genet
2010;42:30–5.
19. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical
trials. Nat Rev Drug Discov 2013;12:358–69.
20. L’Heureux J, Murray JC, Newbury E, Shinkunas L, Simon CM. Public perspectives
on biospecimen procurement: What biorepositories should consider. Biopreserv
Biobank 2013;11:137–43.
21. Kang B, Park J, Cho S, Lee M, Kim N, Min H, Lee S, Park O, Han B. Current status,
challenges, policies, and bioethics of biobanks. Genomics Inform 2013;11:211–7.
22. Tong EK, Fung LC, Stewart SL, Paterniti DA, Dang JH, Chen MS, Jr. Impact of a
biospecimen collection seminar on willingness to donate biospecimens among Chinese
Americans: Results from a randomized, controlled community-based trial. Cancer
Epidemiol Biomarkers Prev 2014;23:392–401.
23. Loffredo CA, Luta G, Wallington S, Makgoeng SB, Selsky C, Mandelblatt JS,
Adams-Campbell LL. Knowledge and willingness to provide research biospecimens
among foreign-born Latinos using safety-net clinics. J Community Health 2013;​
38:652–9.
24. Dang JH, Rodriguez EM, Luque JS, Erwin DO, Meade CD, Chen MS, Jr. Engaging
diverse populations about biospecimen donation for cancer research. J Community
Genet 2014;5:313–27.
25. Koretzky GA. The legacy of the Philadelphia chromosome. J Clin Invest 2007;
117:2030–2.
26. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N,
Deininger MW, et al. Five-year follow-up of patients receiving imatinib for chronic
myeloid leukemia. N Engl J Med 2006;355:2408–17.
27. Moore JH, Asselbergs FW, Williams SM. Bioinformatics challenges for genome-wide
association studies. Bioinformatics 2014;26:445–55.
28. Chowdhury S, Pradhan RN, Sarkar RR. Structural and logical analysis of a comprehensive
hedgehog signaling pathway to identify alternative drug targets for glioma,
colon and pancreatic cancer. PLoS One 2013;8:e69132.
29. Schweizer L, Zhang L. Enhancing cancer drug discovery through novel cell signaling
pathway panel strategy. Cancer Growth Metastasis 2013;6:53–9.
30. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia
in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;​
247:824–30.
31. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and
transformation potency of bcr-abl oncogene products. Science 1990;247:1079–82.
32. Honda H, Hirai H. Model mice for BCR/ABL-positive leukemias. Blood Cells Mol
Dis 2001;27:265–78.
33. Salesse S, Verfaillie CM. BCR/ABL: From molecular mechanisms of leukemia induction
to treatment of chronic myelogenous leukemia. Oncogene 2002;21:8547–59.